Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alzheimer’s Research UK

- PMLiVE

Single genetic test could replace current standard for diagnosing rare developmental disorders

The single genetic test could potentially replace the current standard and reduce costs for the NHS

- PMLiVE

NeuroDerm shares positive phase 3 results for investigational Parkinson’s disease therapy

The progressive neurodegenerative disease affects around ten million people worldwide

- PMLiVE

New genetic risk tool could predict multiple sclerosis in young adults much earlier

Approximately 2.8 million people worldwide are affected by the disabling neurological disease

- PMLiVE

AbbVie’s Produodopa rolled out by NHS England for advanced Parkinson’s patients

The roll out follows NICE’s recommendation of the treatment in October 2023

- PMLiVE

New type of inhibitor drug could prevent microvascular diabetic complications

The drug could prevent conditions including diabetic eye and kidney disease in diabetes

- PMLiVE

UK government approves digital pathology for cancer screening programmes

The approval follows a study that showed digital pathology was as effective as microscopy

- PMLiVE

Researchers suggest erectile dysfunction drugs could reduce risk of Alzheimer’s

The study found that men prescribed PDE5Is were 18% less likely to develop the disease

Biogen Idec building

Biogen to discontinue Alzheimer’s drug Aduhelm in favour of Eisai-partnered Leqembi

The post-marketing confirmatory study of the intravenous treatment will now be terminated

- PMLiVE

UK government announces nearly £50m to expand dementia research sites

The funding will be used to enable more people to take part in clinical trials for dementia

- PMLiVE

Study suggests hearing aids could prevent onset and progression of dementia

People with severe hearing loss had an increased risk of up to 20% of developing dementia

- PMLiVE

Researchers develop new blood test to identify risk of Parkinson’s disease

The findings could help to identify people most likely to benefit from disease-modifying therapies

- PMLiVE

Study programme to investigate blocking brain inflammation in Parkinson’s patients

If successful, the findings could lead to new medicines to treat the neurological disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links